Alyssa Llamas M.P.H.


Education: B.S., University of California, San Diego; M.P.H., The George Washington University


Alyssa Llamas has a diverse background in health policy and public health, with seven years of experience in government, research, and nonprofit settings, in health care access, women’s health, occupational safety and health, immunization, and environmental health.

Alyssa draws from her hands-on experience in advocacy, research, and policymaking to best serve clients. Most recently, she managed the federal policy portfolio at the National Women’s Health Network. At the Jacobs Institute of Women’s Health, Alyssa was first author of a white paper on the public health impacts of state-level abortion restrictions for policymakers, advocates, and the media. As an intern in the Health Office of the Senate Health, Education, Labor and Pensions Committee under Ranking Member Patty Murray, she provided legislative support to senior staff, performed background research on administration officials, and helped conduct committee hearings.

Through her frontline experience, Alyssa understands how federal policy decisions affect state and local partners and how to collaborate effectively with community members. Before graduate school, Alyssa spent five years with the Centers for Disease Control and Prevention (CDC), delivering public health services as a field assignee at the Rocky Mountain Tribal Epidemiology Center and the Idaho Department of Health and Welfare. She also worked at CDC’s National Institute for Occupational Safety and Health, developing education materials and implementing strategies to foster adoption of recommended best practices.

Alyssa received her Bachelor of Science degree from the University of California, San Diego and a Master of Public Health with a concentration in health policy from The George Washington University. Originally from California, she lives in Washington, D.C.

New Legislation to Control Drug Prices: How Do House and Senate Bills Compare? An Update

Commonwealth-Fund 400x200As Congress grapples with an evolving impeachment inquiry, lawmakers have remained focused on lowering prescription drug costs. In December, the House passed the Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3) by a 230–192 vote, largely along party lines with no Democratic defections. House Democratic leaders successfully assuaged grumblings from the Congressional Progressive Caucus that H.R. 3 did not go far enough by doubling the minimum number of drugs subject to price negotiation, among other policy changes....
+ Read More

The Drug Pricing Debate Part II: The Many Acts of Congress

Commonwealth-Fund 400x200As we outlined earlier this spring, congressional action on drug pricing continues to intensify. Key committees have advanced an array of reforms, demonstrating Congress’ intent to finalize legislation this year. We aim to clarify what that might include....
+ Read More

Medicare For All Can Begin In 2021: Here’s How

While Democratic presidential candidates and the newspaper headlines hash out the ideological nuances of a Medicare-based single payer coverage scheme, work is underway to consider how coverage can be expanded to those in need within a realistic timeframe at minimal cost or disruption to the existing system....
+ Read More